280 related articles for article (PubMed ID: 34335561)
1. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
Front Immunol; 2021; 12():638678. PubMed ID: 34335561
[TBL] [Abstract][Full Text] [Related]
2. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
Cui R; Lyu C; Li Q; Jiang Y; Mou N; Yang Z; Liu X; Deng Q; Li L
Hematol Oncol; 2021 Feb; 39(1):75-86. PubMed ID: 32949412
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.
Ma Y; Yang L; Bao Y; Yang Y; Chen L; Zheng M
Front Immunol; 2021; 12():751754. PubMed ID: 34691067
[TBL] [Abstract][Full Text] [Related]
4. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
Wei J; Zhu X; Mao X; Huang L; Meng F; Zhou J
J Immunother Cancer; 2019 Nov; 7(1):315. PubMed ID: 31753002
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
[TBL] [Abstract][Full Text] [Related]
6. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.
Liu W; Huang W; Wang M; Lv R; Li J; Wang Y; Deng S; Yi S; Liu H; Rao Q; Xu Y; Lv L; Qiu L; Zou D; Wang J
Br J Haematol; 2020 Oct; 191(1):126-129. PubMed ID: 32671820
[No Abstract] [Full Text] [Related]
8. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract][Full Text] [Related]
9. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
Liu S; He Z; Wu W; Jin H; Cui Y
Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
Wang Y; Liu Y; Tan X; Pan B; Ge J; Qi K; Cheng H; Cao J; Shi M; Yan Z; Qiao J; Jing G; Wang X; Sang W; Xia R; Zhang X; Li Z; Gale RP; Zheng J; Zhu F; Xu K
Leukemia; 2020 Oct; 34(10):2704-2707. PubMed ID: 32594100
[TBL] [Abstract][Full Text] [Related]
11. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
17. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]